MCID: ADR040
MIFTS: 51

Adrenal Gland Pheochromocytoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Gland Pheochromocytoma

MalaCards integrated aliases for Adrenal Gland Pheochromocytoma:

Name: Adrenal Gland Pheochromocytoma 12 15 17
Pheochromocytoma 72

Classifications:



External Ids:

Disease Ontology 12 DOID:0050892
UMLS 72 C0031511

Summaries for Adrenal Gland Pheochromocytoma

Disease Ontology : 12 A malignant pheochromocytoma that is characterized by overproduction of adrenaline.

MalaCards based summary : Adrenal Gland Pheochromocytoma, also known as pheochromocytoma, is related to malignant pediatric adrenal gland pheochromocytoma and pheochromocytoma, and has symptoms including tremor, fever and abdominal pain. An important gene associated with Adrenal Gland Pheochromocytoma is SOCS3 (Suppressor Of Cytokine Signaling 3), and among its related pathways/superpathways are Development IGF-1 receptor signaling and Prolactin Signaling Pathway. The drugs Bromocriptine and Nebivolol have been mentioned in the context of this disorder. Affiliated tissues include thyroid, adrenal gland and testes, and related phenotypes are cardiovascular system and respiratory system

Related Diseases for Adrenal Gland Pheochromocytoma

Graphical network of the top 20 diseases related to Adrenal Gland Pheochromocytoma:



Diseases related to Adrenal Gland Pheochromocytoma

Symptoms & Phenotypes for Adrenal Gland Pheochromocytoma

UMLS symptoms related to Adrenal Gland Pheochromocytoma:


tremor, fever, abdominal pain, chest pain, headache

MGI Mouse Phenotypes related to Adrenal Gland Pheochromocytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.5 BNIP3 KCNH2 MTOR NOS3 SOCS3 STAT3
2 respiratory system MP:0005388 9.02 ENO2 MTOR NOS3 SOCS3 STAT3

Drugs & Therapeutics for Adrenal Gland Pheochromocytoma

Drugs for Adrenal Gland Pheochromocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 193)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
2
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
3
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
4
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
5
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
6
Doxazosin Approved Phase 4 74191-85-8 3157
7
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
8
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
9 Neurotransmitter Agents Phase 4
10 Adrenergic Agents Phase 4
11 Antihypertensive Agents Phase 4
12 Vasodilator Agents Phase 4
13 Adrenergic Agonists Phase 4
14 Adrenergic beta-Agonists Phase 4
15 Antiparkinson Agents Phase 4
16 Dopamine agonists Phase 4
17 diuretics Phase 4
18 Sodium Chloride Symporter Inhibitors Phase 4
19 Natriuretic Agents Phase 4
20 Giapreza Phase 4
21 Angiotensin Receptor Antagonists Phase 4
22 Angiotensin II Type 1 Receptor Blockers Phase 4
23 Angiotensinogen Phase 4
24 Vasoconstrictor Agents Phase 4
25 Serotonin Uptake Inhibitors Phase 4
26 Antidepressive Agents Phase 4
27 Serotonin Receptor Agonists Phase 4
28 Analgesics, Non-Narcotic Phase 4
29 Neurotransmitter Uptake Inhibitors Phase 4
30 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
31 Serotonin Agents Phase 4
32 Psychotropic Drugs Phase 4
33 Duloxetine Hydrochloride Phase 4
34
Tyramine Investigational, Nutraceutical Phase 4 51-67-2 5610
35
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
36
Ifosfamide Approved Phase 3 3778-73-2 3690
37
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
38
Lenograstim Approved, Investigational Phase 3 135968-09-1
39
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
40 Calamus Phase 3
41 Anti-Bacterial Agents Phase 3
42 Antibiotics, Antitubercular Phase 3
43
Liposomal doxorubicin Phase 3 31703
44 Topoisomerase Inhibitors Phase 3
45
Isophosphamide mustard Phase 3 0
46
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
47
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
48
Indinavir Approved Phase 2 150378-17-9 5362440
49
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
50
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
2 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
3 Pheochromocytoma Randomised Study Comparing Adrenoreceptor Inhibiting Agents for Preoperative Treatment Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
4 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up Completed NCT01959711 Phase 4
5 Effectiveness of the Norepinephrine and Serotonin Reuptake Inhibitor Levomilnacipran in Healthy Males Recruiting NCT03249311 Phase 4 Levomilnacipran;Duloxetine;Placebos
6 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
7 An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
8 High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms. Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
9 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
10 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
11 Randomized Controlled Trial of Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
12 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
13 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
14 A Phase II Study of 131I-labeled Metaiodobenzylguanidine (MIBG) for Treatment of Patients With Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
15 A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
16 Phase II Study of RAD001monotherapy in Patients With Unresectable Pheochromocytoma or Extra-adrenal Paraganglioma or Non-functioning Carcinoid Completed NCT01152827 Phase 2 RAD001
17 A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors Completed NCT00923481 Phase 2 Fostamatinib disodium
18 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
19 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
20 A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors Completed NCT00843531 Phase 2 RAD001;erlotinib
21 Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder Completed NCT02437383 Phase 2 Propranolol ER;Placebo
22 A Phase 2 Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors Completed NCT00566995 Phase 2 ZACTIMA (Vandetanib) (ZD6474)
23 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL) Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
24 Open Access Protocol of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors Recruiting NCT00107289 Phase 2
25 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Recruiting NCT03839498 Phase 2 Axitinib
26 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting NCT03034200 Phase 2 ONC201
27 Lidocaine Infusion in Functional Endoscopic Sinus Surgery Recruiting NCT03047070 Phase 2 Lidocaine;Normal saline
28 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;F-18-FDG;Amino Acid solution
29 A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer Recruiting NCT03165721 Phase 2 SGI-110 (guadecitabine)
30 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib S-malate
31 Clinical Study of the Use of Yttrium-90 (90Y) and/or Lutecium-177 (177Lu) DOTATATE (DOTA-0-Tyr3-Octreotate) in the Treatment of Disseminated and / or Symptomatic Tumors With Somatostatin Receptor Overexpression Recruiting NCT04029428 Phase 2 90Y-DOTATATE;(177Lu-DOTAOTyr3)Octreotate;90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
32 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
33 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
34 Phase II Trial of LBlOO, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma Recruiting NCT03027388 Phase 2 LB-100
35 Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma Active, not recruiting NCT03008369 Phase 2 Lenvatinib
36 A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma Active, not recruiting NCT01635907 Phase 2 Dovitinib
37 A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Active, not recruiting NCT00843037 Phase 2 Sunitinib
38 A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
39 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2 Axitinib (AG-013736)
40 Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA) Not yet recruiting NCT03946527 Phase 2 Lanreotide
41 Phase I/II Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3 OCTREOTATE (177Lu-DOTATATE) in Children With Neuroendocrine Tumor, Neuroblastoma, or Pheochromocytoma/Paraganglioma Not yet recruiting NCT03923257 Phase 1, Phase 2 177Lu-DOTA-tyr3-OCTREOTATE
42 Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
43 A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2 Pazopanib Hydrochloride
44 Treatment Targets for Chronic Hypertension in Pregnancy Withdrawn NCT00194974 Phase 1, Phase 2 methyldopa;labetalol;nifedipine;clonidine
45 Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn NCT00770705 Phase 2 Phenoxybenzamine
46 Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid Completed NCT00339131 Phase 1 Ultratrace iobenguane I 131
47 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1
48 A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
49 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
50 A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib

Search NIH Clinical Center for Adrenal Gland Pheochromocytoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Metyrosine
Phenoxybenzamine
Phenoxybenzamine Hydrochloride
Propranolol
Propranolol Hydrochloride

Genetic Tests for Adrenal Gland Pheochromocytoma

Anatomical Context for Adrenal Gland Pheochromocytoma

MalaCards organs/tissues related to Adrenal Gland Pheochromocytoma:

41
Thyroid, Adrenal Gland, Testes, Brain, Heart, Pituitary, Bone

Publications for Adrenal Gland Pheochromocytoma

Articles related to Adrenal Gland Pheochromocytoma:

(show top 50) (show all 15077)
# Title Authors PMID Year
1
Long non-coding RNA GAS5 promotes PC12 cells differentiation into Tuj1-positive neuron-like cells and induces cell cycle arrest. 38
31397350 2019
2
LncRNA ANRIL protects against oxygen and glucose deprivation (OGD)-induced injury in PC-12 cells: potential role in ischaemic stroke. 38
31174432 2019
3
Concurrent Metastatic Pheochromocytomas and Lung Adenocarcinoma on 18F-FDG and 68Ga-DOTATATE PET/CT Images. 38
31021913 2019
4
Circular RNA circ_0000950 promotes neuron apoptosis, suppresses neurite outgrowth and elevates inflammatory cytokines levels via directly sponging miR-103 in Alzheimer's disease. 38
31373242 2019
5
A conducting neural interface of polyurethane/silk-functionalized multiwall carbon nanotubes with enhanced mechanical strength for neuroregeneration. 38
31147022 2019
6
Pediatric pheochromocytoma: current status of diagnostic imaging and treatment procedures. 38
31246590 2019
7
18F-FDOPA PET Compared With 123I-Metaiodobenzylguanidine Scintigraphy and 18F-FDG PET in Secreting Sporadic Pheochromocytoma. 38
31306205 2019
8
Laparoscopic treatment of a cystic pheochromocytoma of 6cms: A challenging case. 38
31388495 2019
9
Pheochromocytoma and Pregnancy. 38
31345526 2019
10
Long noncoding RNA MEG3 silencing protects against hypoxia-induced pheochromocytoma-12 cell injury through inhibition of TIMP2 promoter methylation. 38
31392726 2019
11
Pheochromocytoma and paraganglioma: Clinical feature based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. 38
31370000 2019
12
SDHx-related pheochromocytoma/paraganglioma - genetic, clinical, and treatment outcomes in a series of 30 patients from a single center. 38
31104306 2019
13
3P association (3PAs): Pituitary adenoma and pheochromocytoma/paraganglioma. A heterogeneous clinical syndrome associated with different gene mutations. 38
31431315 2019
14
Fibroblast deficiency of insulin-like growth factor 1 receptor type 1 (IGF1R) impairs initial steps of murine pheochromocytoma development. 38
31185266 2019
15
Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy. 38
31397861 2019
16
Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study. 38
31383958 2019
17
Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma. 38
31390824 2019
18
Ultrasound-guided quadratus lumborum block type 2 associated to continuous intravenous infusion of dexmetomidine for anesthesiologic management in laparoscopic adrenalectomy for pheochromocytoma: could it be a safe strategy? 38
30945518 2019
19
ISMP Adverse Drug Reactions: Pheochromocytoma Crisis Induced by Metoclopramide Baclofen Dependence Following High-Dose Therapy Fatal Cardiotoxicity Following High-Dose Cyclophosphamide Acute Anterograde Amnestic Syndrome Induced by Fentanyl Ivermectin-Induced Toxic Epidermal Necrolysis Pembrolizumab-Induced Type 1 Diabetes. 38
31320773 2019
20
[Diagnosis and surgical treatment of massive adrenal area tumor with tumor thrombus]. 38
31420622 2019
21
Adrenal morphology and associated comorbidities in congenital adrenal hyperplasia. 38
31001843 2019
22
Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A in children: a single centre experience. 38
31343983 2019
23
Knockdown of microRNA-17-5p Enhances the Neuroprotective Effect of Act A/Smads Signal Loop After Ischemic Injury. 38
31093905 2019
24
Pheochromocytoma and Paraganglioma. 38
31390501 2019
25
Ovarian Steroid Cell Tumor in an Adolescent With Von Hippel-Lindau Syndrome: A Case Report and Review of the Literature. 38
31433374 2019
26
Addressing delays in the diagnosis of pheochromocytoma/paraganglioma. 38
31429343 2019
27
Pheochromocytoma- and paraganglioma-triggered Takotsubo syndrome. 38
31399912 2019
28
Presentation, Treatment, Histology, and Outcomes in Adrenal Medullary Hyperplasia Compared With Pheochromocytoma. 38
31384714 2019
29
Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. 38
30877234 2019
30
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance. 38
31375625 2019
31
Proapoptotic effects of 2,5‑hexanedione on pheochromocytoma cells via oxidative injury. 38
31432125 2019
32
Phenylethanoid glycosides from Paraboea martinii protect rat pheochromocytoma (PC12) cells from hydrogen peroxide-induced cell injury. 38
31409200 2019
33
Triclosan induces PC12 cells injury is accompanied by inhibition of AKT/mTOR and activation of p38 pathway. 38
31381933 2019
34
Sodium nitroprusside induces H-Ras depalmitoylation and alters the cellular response to hypoxia in differentiated and undifferentiated PC12 cells. 38
31429100 2019
35
The sulfation of biomimetic glycosaminoglycan substrates controls binding of growth factors and subsequent neural and glial cell growth. 38
31407727 2019
36
Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine. 38
31330766 2019
37
Pheochromocytoma: Positive on 131I-MIBG Single-Photon Emission Computed Tomography-Computed Tomography and Negative on 68Ga DOTANOC Positron Emission Tomography-Computed Tomography. 38
31293315 2019
38
Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent 211At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice. 38
31078058 2019
39
Effects of geldanamycin on neurite outgrowth-related proteins and kinases in nerve growth factor-differentiated pheochromocytoma 12 cells. 38
31402210 2019
40
Abnormal glucose tolerance in a patient with pheochromocytoma and ACTH-independent subclinical Cushing's syndrome involving the same adrenal gland. 38
31256733 2019
41
Brown adipose activation and reversible beige coloration in adipose tissue with multiple accumulations of 18F-fluorodeoxyglucose in sporadic paraganglioma: A case report. 38
31360497 2019
42
Challenging risk factors for right and left laparoscopic adrenalectomy: A single centre experience with 272 cases. 38
31136115 2019
43
Indocyanine green fluorescence imaging during partial adrenalectomy. 38
31342258 2019
44
Precision Surgery for Pheochromocytomas and Paragangliomas. 38
31307109 2019
45
Carvacrol Protects Against 6-Hydroxydopamine-Induced Neurotoxicity in In Vivo and In Vitro Models of Parkinson's Disease. 38
31364033 2019
46
Reversing ROS-mediated neurotoxicity by chlorogenic acid involves its direct antioxidant activity and activation of Nrf2-ARE signaling pathway. 38
30951611 2019
47
Acid sphingomyelinase - a regulator of canonical transient receptor potential channel 6 (TRPC6) activity. 38
31310676 2019
48
Tandem Mass Spectrometry Imaging Reveals Distinct Accumulation Patterns of Steroid Structural Isomers in Human Adrenal Glands. 38
31204806 2019
49
The role of the antidiabetic drug metformin in the treatment of endocrine tumors. 38
31307011 2019
50
Tumor suppressor KIF1Bβ regulates mitochondrial apoptosis in collaboration with YME1L1. 38
30859632 2019

Variations for Adrenal Gland Pheochromocytoma

Cosmic variations for Adrenal Gland Pheochromocytoma:

9 (show top 50) (show all 62)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM100047 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.389T>G p.V130G 3:10146562-10146562 6
2 COSM14283 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.491A>G p.Q164R 3:10149814-10149814 6
3 COSM17662 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.492G>T p.Q164H 3:10149815-10149815 6
4 COSM18097 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.482G>A p.R161Q 3:10149805-10149805 6
5 COSM14311 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.499C>T p.R167W 3:10149822-10149822 6
6 COSM14321 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.227T>A p.F76Y 3:10142074-10142074 6
7 COSM5885100 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>A p.V84M 3:10142097-10142097 6
8 COSM6444479 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.260T>C p.V87A 3:10142107-10142107 6
9 COSM144975 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.475A>G p.K159E 3:10149798-10149798 6
10 COSM17982 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.496G>T p.V166F 3:10149819-10149819 6
11 COSM236660 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>C p.V84L 3:10142097-10142097 6
12 COSM17666 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.593T>C p.L198P 3:10149916-10149916 6
13 COSM10662 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.743G>A p.R248Q 17:7674220-7674220 6
14 COSM44914 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 6
15 COSM43678 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.305C>T p.T102I 17:7676064-7676064 6
16 COSM966 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.1900T>C p.C634R 10:43114500-43114500 6
17 COSM965 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.2753T>C p.M918T 10:43121968-43121968 6
18 COSM220089 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1885G>A p.Q616fs*4 17:31225134-31225134 6
19 COSM329092 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1721+3A>T p.A548fs*13 17:31221932-31221932 6
20 COSM30670 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7646C>G p.S2549* 17:31356490-31356490 6
21 COSM329090 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.226G>T p.E76* 17:31159031-31159031 6
22 COSM5885098 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.5665G>T p.E1889* 17:31330351-31330351 6
23 COSM329093 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1722-1G>A p.? 17:31223443-31223443 6
24 COSM330587 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.205-1G>C p.R69Xfs*7 17:31159009-31159009 6
25 COSM327926 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3158C>A p.S1053* 17:31230886-31230886 6
26 COSM327927 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7582C>T p.Q2528* 17:31352381-31352381 6
27 COSM33676 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.6855C>A p.Y2285* 17:31338739-31338739 6
28 COSM329087 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.4558C>T p.Q1520* 17:31260496-31260496 6
29 COSM1710108 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7300C>T p.Q2434* 17:31349230-31349230 6
30 COSM24441 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3721C>T p.R1241* 17:31235623-31235623 6
31 COSM330588 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.2409+1G>A p.A776_Q803del 17:31227607-31227607 6
32 COSM329089 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1466A>G p.Y489C 17:31214524-31214524 6
33 COSM707 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.3029C>T p.T1010I 7:116771936-116771936 6
34 COSM5967149 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.607T>A p.S203T 7:116699691-116699691 6
35 COSM5946188 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.352A>T p.M118L 7:116699436-116699436 6
36 COSM5945782 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7393G>A p.G2465S 12:49039461-49039461 6
37 COSM6342201 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.6797T>C p.F2266S 12:49040163-49040163 6
38 COSM144597 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7019T>C p.L2340P 12:49039941-49039941 6
39 COSM5945788 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7954C>T p.R2652W 12:49038592-49038592 6
40 COSM5945789 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.14856C>A p.N4952K 12:49026300-49026300 6
41 COSM5945787 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.11854C>G p.L3952V 12:49032041-49032041 6
42 COSM5945783 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.14858A>G p.N4953S 12:49026298-49026298 6
43 COSM499 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.182A>G p.Q61R 11:533874-533874 6
44 COSM496 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.181C>A p.Q61K 11:533875-533875 6
45 COSM486 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.37G>C p.G13R 11:534286-534286 6
46 COSM1732355 H3-3A adrenal gland,adrenal gland,pheochromocytoma,NS c.103G>T p.G35W 1:226064454-226064454 6
47 COSM27887 GNAS adrenal gland,adrenal gland,pheochromocytoma,NS c.601C>T p.R201C 20:58909365-58909365 6
48 COSM19176 FGFR1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1638C>A p.N546K 8:38417331-38417331 6
49 COSM6188660 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1592C>T p.P531L 2:46380264-46380264 6
50 COSM6995498 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1588G>C p.A530P 2:46380260-46380260 6

Expression for Adrenal Gland Pheochromocytoma

Search GEO for disease gene expression data for Adrenal Gland Pheochromocytoma.

Pathways for Adrenal Gland Pheochromocytoma

Pathways related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.13 STAT3 SOCS3 MTOR
2
Show member pathways
12.07 STAT3 SOCS3 NOS3 MTOR
3
Show member pathways
11.98 STAT3 SOCS3 MTOR
4 11.87 STAT3 NOS3 MTOR
5 11.55 STAT3 SOCS3 MTOR
6 11.55 TTR STAT3 SOCS3
7
Show member pathways
11.3 STAT3 SOCS3 NOS3 MTOR
8 11.28 STAT3 MTOR
9 11.27 STAT3 SOCS3 MTOR
10 11.24 STAT3 SOCS3
11
Show member pathways
11.23 STAT3 BNIP3
12
Show member pathways
11.2 STAT3 SOCS3
13 11.18 STAT3 SOCS3
14 11.1 STAT3 SOCS3
15 11.07 STAT3 SOCS3 MTOR
16 11.05 STAT3 SOCS3
17 11 NOS3 MTOR
18
Show member pathways
10.99 STAT3 SOCS3
19
Show member pathways
10.96 STAT3 SOCS3
20 10.96 STAT3 NOS3 MTOR ENO2
21 10.91 TTR STAT3 SOCS3
22 10.74 STAT3 SOCS3

GO Terms for Adrenal Gland Pheochromocytoma

Biological processes related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.62 STAT3 SOCS3 BNIP3 ANXA5
2 positive regulation of blood vessel endothelial cell migration GO:0043536 9.43 NOS3 MIR210
3 cardiac muscle contraction GO:0060048 9.4 MTOR KCNH2
4 positive regulation of macroautophagy GO:0016239 9.37 TRIM13 BNIP3
5 positive regulation of angiogenesis GO:0045766 9.33 STAT3 NOS3 MIR210
6 JAK-STAT cascade GO:0007259 9.26 STAT3 SOCS3
7 interleukin-6-mediated signaling pathway GO:0070102 8.96 STAT3 SOCS3
8 regulation of mitochondrial membrane permeability GO:0046902 8.62 STAT3 BNIP3

Molecular functions related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.02 TTR STAT3 MTOR KCNH2 BNIP3

Sources for Adrenal Gland Pheochromocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....